GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kyorin Pharmaceutical Co Ltd (TSE:4569) » Definitions » Shiller PE Ratio

Kyorin Pharmaceutical Co (TSE:4569) Shiller PE Ratio : 13.72 (As of Mar. 17, 2025)


View and export this data going back to 2001. Start your Free Trial

What is Kyorin Pharmaceutical Co Shiller PE Ratio?

As of today (2025-03-17), Kyorin Pharmaceutical Co's current share price is 円1597.00. Kyorin Pharmaceutical Co's E10 for the quarter that ended in Jun. 2024 was 円116.41. Kyorin Pharmaceutical Co's Shiller PE Ratio for today is 13.72.

The historical rank and industry rank for Kyorin Pharmaceutical Co's Shiller PE Ratio or its related term are showing as below:

TSE:4569' s Shiller PE Ratio Range Over the Past 10 Years
Min: 11.54   Med: 14.39   Max: 19.92
Current: 13.68

During the past years, Kyorin Pharmaceutical Co's highest Shiller PE Ratio was 19.92. The lowest was 11.54. And the median was 14.39.

TSE:4569's Shiller PE Ratio is ranked better than
79.09% of 464 companies
in the Drug Manufacturers industry
Industry Median: 23.845 vs TSE:4569: 13.68

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Kyorin Pharmaceutical Co's adjusted earnings per share data for the three months ended in Jun. 2024 was 円15.420. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is 円116.41 for the trailing ten years ended in Jun. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Kyorin Pharmaceutical Co Shiller PE Ratio Historical Data

The historical data trend for Kyorin Pharmaceutical Co's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyorin Pharmaceutical Co Shiller PE Ratio Chart

Kyorin Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.81 14.41 13.77 13.83 15.40

Kyorin Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.00 14.96 15.40 14.62 13.04

Competitive Comparison of Kyorin Pharmaceutical Co's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyorin Pharmaceutical Co's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Kyorin Pharmaceutical Co's Shiller PE Ratio falls into.



Kyorin Pharmaceutical Co Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Kyorin Pharmaceutical Co's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=1597.00/116.41
=13.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyorin Pharmaceutical Co's E10 for the quarter that ended in Jun. 2024 is calculated as:

For example, Kyorin Pharmaceutical Co's adjusted earnings per share data for the three months ended in Jun. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=15.42/108.2000*108.2000
=15.420

Current CPI (Jun. 2024) = 108.2000.

Kyorin Pharmaceutical Co Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201409 10.900 98.500 11.973
201412 81.320 97.900 89.876
201503 33.530 97.900 37.058
201506 23.760 98.400 26.126
201509 16.340 98.500 17.949
201512 106.210 98.100 117.145
201603 37.970 97.900 41.965
201606 35.150 98.100 38.769
201609 1.410 98.000 1.557
201612 27.676 98.400 30.432
201703 35.119 98.100 38.735
201706 32.540 98.500 35.744
201709 -15.682 98.800 -17.174
201712 66.270 99.400 72.137
201803 6.150 99.200 6.708
201806 14.600 99.200 15.925
201809 15.440 99.900 16.723
201812 44.760 99.700 48.576
201903 29.880 99.700 32.427
201906 22.360 99.800 24.242
201909 -7.800 100.100 -8.431
201912 61.795 100.500 66.530
202003 30.984 100.300 33.424
202006 28.100 99.900 30.435
202009 8.880 99.900 9.618
202012 41.650 99.300 45.383
202103 28.360 99.900 30.716
202106 -8.060 99.500 -8.765
202109 10.174 100.100 10.997
202112 41.220 100.100 44.555
202203 25.280 101.100 27.055
202206 20.650 101.800 21.948
202209 1.030 103.100 1.081
202212 54.710 104.100 56.865
202303 6.038 104.400 6.258
202306 11.810 105.200 12.147
202309 21.160 106.200 21.558
202312 35.231 106.800 35.693
202403 24.509 107.200 24.738
202406 15.420 108.200 15.420

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Kyorin Pharmaceutical Co  (TSE:4569) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Kyorin Pharmaceutical Co Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Kyorin Pharmaceutical Co's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyorin Pharmaceutical Co Business Description

Traded in Other Exchanges
Address
6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.

Kyorin Pharmaceutical Co Headlines

No Headlines